Trial Profile
Subcutaneous Aspart Insulin and Point of Care Beta Hydroxybutyrate Testing: A New Paradigm for the Management of Diabetic Ketoacidosis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin aspart (Primary) ; Insulin aspart (Primary) ; Insulin
- Indications Diabetic ketoacidosis
- Focus Therapeutic Use
- 18 Aug 2012 Actual end date (1 Dec 2007) added as reported by ClinicalTrials.gov.
- 15 Aug 2012 Actual initiation date (1 Jan 2005) added as reported by ClinicalTrials.gov.
- 23 Jun 2009 New trial record